Loading...
Header Logo
Keywords
Last Name
Institution

SHIMIN HU

TitleAssistant Professor
InstitutionMD Anderson
DepartmentHematopathology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Li S, Weiss VL, Wang XJ, Desai PA, Hu S, Yin CC, Tang G, Reddy NM, Medeiros LJ, Lin P. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. Am J Surg Pathol. 2016 Feb; 40(2):253-61. PMID: 26448193.
      View in: PubMed
    2. Liu W, Hu S, Konopleva M, Khoury JD, Kalhor N, Tang G, Bueso-Ramos CE, Jorgensen JL, Lin P, Medeiros LJ, Lu X. De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis. Pediatr Hematol Oncol. 2015; 32(8):535-47. PMID: 26558423.
      View in: PubMed
    3. Wang XJ, Medeiros LJ, Lin P, Yin CC, Hu S, Thompson MA, Li S. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma. Am J Surg Pathol. 2015 Sep; 39(9):1250-8. PMID: 25828389.
      View in: PubMed
    4. Tang G, Fu B, Hu S, Lu X, Tang Z, Li S, Jabbar K, Khoury JD, Medeiros LJ, Wang SA. Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. Am J Hematol. 2015 Oct; 90(10):882-7. PMID: 26148174.
      View in: PubMed
    5. Wang W, Hu S, Lu X, Young KH, Medeiros LJ. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. Am J Surg Pathol. 2015 Aug; 39(8):1132-9. PMID: 25828391.
      View in: PubMed
    6. Wang W, Xie W, Hu S. Cup-like blasts in B-lymphoblastic leukaemia. Br J Haematol. 2015 Sep; 170(5):596. PMID: 26132718.
      View in: PubMed
    7. Tang G, Goswami RS, Liang CS, Bueso-Ramos CE, Hu S, DiNardo C, Medeiros LJ. Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant. Am J Clin Pathol. 2015 Jul; 144(1):78-86. PMID: 26071464.
      View in: PubMed
    8. Chen Z, Wang W, Verstovsek S, Cortes JE, Medeiros LJ, Hu S. Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm. Int J Lab Hematol. 2015 Dec; 37(6):e150-2. PMID: 26086872.
      View in: PubMed
    9. Chen Z, Wang W, Rich A, Tang G, Hu S. Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases. Am J Hematol. 2015 Aug; 90(8):E146-8. PMID: 25960187.
      View in: PubMed
    10. Liu H, Wang W, Tang G, Yin CC, Muzzafar T, Medeiros LJ, Hu S. Lymphomatous variant of hairy cell leukaemia: a distinctive presentation mimicking low-grade B-cell lymphoma. Histopathology. 2015 Nov; 67(5):740-5. PMID: 25809821.
      View in: PubMed
    11. Wang W, Hu S. Neoplastic plasma cells mimic mature neutrophils in plasma cell myeloma with t(11;14)(q13;q32). Blood. 2015 Apr 30; 125(18):2875. PMID: 26120642.
      View in: PubMed
    12. Wang W, Tang G, Cortes JE, Liu H, Ai D, Yin CC, Li S, Khoury JD, Bueso-Ramos C, Medeiros LJ, Hu S. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol. 2015 Apr 08; 8:32. PMID: 25888368.
      View in: PubMed
    13. Li Y, Hu S, Zuo Z, Hong M, Lin P, Li S, Konoplev S, Wang Z, Khoury JD, Young KH, Medeiros LJ, Yin CC. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol. 2015 Jun; 28(6):787-98. PMID: 25743023.
      View in: PubMed
    14. Wang XI, Yin CC, Qazilbash MH, Hu S, Lu G. Clinical significance of acquired cytogenetic clones in patients with treated follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2015 May; 15(5):262-9. PMID: 25573378.
      View in: PubMed
    15. Goswami RS, Liang CS, Bueso-Ramos CE, Hu S, Goswami M, Yin CC, Lu G, Medeiros LJ, Tang G. Isolated +15 in bone marrow: disease-associated or a benign finding? Leuk Res. 2015 Jan; 39(1):72-6. PMID: 25435027.
      View in: PubMed
    16. Zuo Z, Maiti S, Hu S, Loghavi S, Calin GA, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Cooper LJ, Bueso-Ramos CE. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol. 2015 Mar; 28(3):373-82. PMID: 25216221.
      View in: PubMed
    17. Tang G, Zhang L, Fu B, Hu J, Lu X, Hu S, Patel A, Goswami M, Khoury JD, Garcia-Manero G, Medeiros LJ, Wang SA. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol. 2014 Aug; 89(8):813-8. PMID: 24782398.
      View in: PubMed
    18. Tang G, Lu X, Wang SA, Roney EK, Zhang L, Hu S, Lu G, Medeiros LJ, Patel A. Homozygous inv(11)(q21q23) and MLL gene rearrangement in two patients with myeloid neoplasms. Int J Clin Exp Pathol. 2014; 7(6):3196-201. PMID: 25031740.
      View in: PubMed
    19. Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O'Brien S, Daver N. Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):e115-8. PMID: 24589157.
      View in: PubMed
    20. Hu S, Bueso-Ramos CE, Verstovsek S, Miranda RN, Yin CC, McDonnell T, Medeiros LJ, Lin P. Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):629-33. PMID: 23800601.
      View in: PubMed
    21. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Møller MB, Medeiros LJ, Young KH. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 16; 121(20):4021-31; quiz 4250. PMID: 23449635.
      View in: PubMed
    22. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM, Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhao X, Winter JN, Zhang M, Li L, Møller MB, Piris MA, Li Y, Go RS, Wu L, Medeiros LJ, Young KH. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013 Apr 04; 121(14):2715-24. PMID: 23343832.
      View in: PubMed
    23. Hu S, Young KH, Konoplev SN, Medeiros LJ. Follicular T-cell lymphoma: a member of an emerging family of follicular helper T-cell derived T-cell lymphomas. Hum Pathol. 2012 Nov; 43(11):1789-98. PMID: 22959759.
      View in: PubMed
    24. Manola A, Kourelis TV, Busman B, Hu S, Marks P, Thompson PD. Mastocytosis causing refractory hypotension after coronary angiography. Int J Cardiol. 2012 Apr 19; 156(2):e43-4. PMID: 21917341.
      View in: PubMed
    25. Mei Y, Hahn AA, Hu S, Yang X. The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2. J Biol Chem. 2011 Oct 14; 286(41):35380-7. PMID: 21849505.
      View in: PubMed
    26. Hu S, Mrak RE, Goldblatt PJ. Tripartite components of a hepatocellular carcinoma with distinct immunohistochemical and metastatic features. Conn Med. 2010 Feb; 74(2):79-83. PMID: 20218042.
      View in: PubMed
    27. Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, Shen H, Yang X, Chen YH. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 2008 May 02; 133(3):415-26. PMID: 18455983.
      View in: PubMed
    28. Park SM, Hu S, Lee TH, Yang X. Ubiquitination mediated by inhibitor of apoptosis proteins. Methods Enzymol. 2008; 446:225-35. PMID: 18603125.
      View in: PubMed
    29. Hu S, Alcivar A, Qu L, Tang J, Yang X. CIAP2 inhibits anigen receptor signaling by targeting Bcl10 for degredation. Cell Cycle. 2006 Jul; 5(13):1438-42. PMID: 16775419.
      View in: PubMed
    30. Hu S, Du MQ, Park SM, Alcivar A, Qu L, Gupta S, Tang J, Baens M, Ye H, Lee TH, Marynen P, Riley JL, Yang X. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest. 2006 Jan; 116(1):174-81. PMID: 16395405.
      View in: PubMed
    31. Hu SX, Wang S, Wang JP, Mills GB, Zhou Y, Xu HJ. Expression of endogenous granzyme B in a subset of human primary breast carcinomas. Br J Cancer. 2003 Jul 07; 89(1):135-9. PMID: 12838314.
      View in: PubMed
    32. Alcivar A, Hu S, Tang J, Yang X. DEDD and DEDD2 associate with caspase-8/10 and signal cell death. Oncogene. 2003 Jan 16; 22(2):291-7. PMID: 12527898.
      View in: PubMed
    33. Hu S, Yang X. Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. J Biol Chem. 2003 Mar 21; 278(12):10055-60. PMID: 12525502.
      View in: PubMed
    34. Hu S, Yang X. dFADD, a novel death domain-containing adapter protein for the Drosophila caspase DREDD. J Biol Chem. 2000 Oct 06; 275(40):30761-4. PMID: 10934188.
      View in: PubMed
    35. Hu S, Tamada K, Ni J, Vincenz C, Chen L. Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily. Genomics. 1999 Nov 15; 62(1):103-7. PMID: 10585776.
      View in: PubMed
    36. Guo RF, Ward PA, Hu SM, McDuffie JE, Huber-Lang M, Shi MM. Molecular cloning and characterization of a novel human CC chemokine, SCYA26. Genomics. 1999 Jun 15; 58(3):313-7. PMID: 10373330.
      View in: PubMed
    37. Hu S, Snipas SJ, Vincenz C, Salvesen G, Dixit VM. Caspase-14 is a novel developmentally regulated protease. J Biol Chem. 1998 Nov 06; 273(45):29648-53. PMID: 9792675.
      View in: PubMed
    38. Xu HJ, Zhou Y, Ji W, Perng GS, Kruzelock R, Kong CT, Bast RC, Mills GB, Li J, Hu SX. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene. 1997 Nov 20; 15(21):2589-96. PMID: 9399646.
      View in: PubMed
    39. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem. 1997 Jul 11; 272(28):17255-7. PMID: 9211860.
      View in: PubMed
    40. Hu S, Vincenz C, Buller M, Dixit VM. A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. J Biol Chem. 1997 Apr 11; 272(15):9621-4. PMID: 9092488.
      View in: PubMed
    41. Cagle PT, el-Naggar AK, Xu HJ, Hu SX, Benedict WF. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. Am J Pathol. 1997 Feb; 150(2):393-400. PMID: 9033254.
      View in: PubMed
    42. Xu HJ, Xu K, Zhou Y, Li J, Benedict WF, Hu SX. Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein. Proc Natl Acad Sci U S A. 1994 Oct 11; 91(21):9837-41. PMID: 7937901.
      View in: PubMed
    43. Zhou Y, Li J, Xu K, Hu SX, Benedict WF, Xu HJ. Further characterization of retinoblastoma gene-mediated cell growth and tumor suppression in human cancer cells. Proc Natl Acad Sci U S A. 1994 May 10; 91(10):4165-9. PMID: 8183886.
      View in: PubMed
    44. Xu HJ, Quinlan DC, Davidson AG, Hu SX, Summers CL, Li J, Benedict WF. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst. 1994 May 04; 86(9):695-9. PMID: 8158700.
      View in: PubMed
    45. Xu HJ, Cairns P, Hu SX, Knowles MA, Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer. 1993 Mar 12; 53(5):781-4. PMID: 8449603.
      View in: PubMed
    46. Banerjee A, Xu HJ, Hu SX, Araujo D, Takahashi R, Stanbridge EJ, Benedict WF. Changes in growth and tumorigenicity following reconstitution of retinoblastoma gene function in various human cancer cell types by microcell transfer of chromosome 13. Cancer Res. 1992 Nov 15; 52(22):6297-304. PMID: 1423276.
      View in: PubMed
    47. Banerjee A, Srivatsan E, Hashimoto T, Takahashi R, Xu HJ, Hu SX, Benedict WF. Immortalization of fibroblasts from two patients with hereditary retinoblastoma. Anticancer Res. 1992 Sep-Oct; 12(5):1347-54. PMID: 1359829.
      View in: PubMed
    48. Ishikawa J, Xu HJ, Hu SX, Yandell DW, Maeda S, Kamidono S, Benedict WF, Takahashi R. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res. 1991 Oct 15; 51(20):5736-43. PMID: 1913692.
      View in: PubMed
    49. Xu HJ, Sumegi J, Hu SX, Banerjee A, Uzvolgyi E, Klein G, Benedict WF. Intraocular tumor formation of RB reconstituted retinoblastoma cells. Cancer Res. 1991 Aug 15; 51(16):4481-5. PMID: 1868470.
      View in: PubMed
    50. Xu HJ, Hu SX, Benedict WF. Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level. Oncogene. 1991 Jul; 6(7):1139-46. PMID: 1861863.
      View in: PubMed
    51. Xu HJ, Hu SX, Cagle PT, Moore GE, Benedict WF. Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res. 1991 May 15; 51(10):2735-9. PMID: 1850661.
      View in: PubMed
    52. Hashimoto T, Takahashi R, Yandell DW, Xu HJ, Hu SX, Gunnell S, Benedict WF. Characterization of intragenic deletions in two sporadic germinal mutation cases of retinoblastoma resulting in abnormal gene expression. Oncogene. 1991 Mar; 6(3):463-9. PMID: 2011402.
      View in: PubMed
    53. Benedict WF, Xu HJ, Hu SX, Takahashi R. Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest. 1990 Apr; 85(4):988-93. PMID: 2180983.
      View in: PubMed
    54. Xu HJ, Hu SX, Hashimoto T, Takahashi R, Benedict WF. The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells. Oncogene. 1989 Jun; 4(6):807-12. PMID: 2471953.
      View in: PubMed
    55. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia. Journal of Hematology and Oncology. 8.
    56. T-lymphoid or T/myeloid blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. International Journal of Laboratory Hematology.
    57. BCR-ABL1-negative acute myeloid leukaemia relapsing as BCR-ABL1-positive disease. British Journal of Haematology.
    58. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Modern Pathology.
    59. Tetraploidy/near-tetraploidy acute myeloid leukemia. Leukemia Research. 53:20-27.
    60. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients. Journal of Hematology and Oncology. 8.
    61. Double-hit follicular lymphoma with MYC and BCL2 translocations. Human Pathology. 58:72-77.
    62. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 127:2742-2750.
    63. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 126:1699-1706.
    64. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia.
    65. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia.
    66. Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. Modern Pathology.
    67. Mantle Cell Lymphoma With MYC Rearrangement. American Journal of Surgical Pathology.
    68. The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia. Modern Pathology.
    69. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Annals of Hematology. 1-4.
    70. Hepatitis B virus-associated diffuse large B-cell lymphoma. Oncotarget. 6:25061-25075.
    71. De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated with Poor Prognosis. Pediatric Hematology and Oncology. 32:535-547.
    72. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia.
    73. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood Cancer Journal. 6.
    74. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. Blood Cancer Journal. 6.
    75. ALK-positive large b-cell lymphoma. American Journal of Surgical Pathology. 41:25-38.
    76. Clinical significance of acquired loss of the X chromosome in bone marrow. Leukemia Research. 47:109-113.
    HU's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description